Aliso Viejo, CA – April 20, 2022 – MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced the successful completion of its first enrollment in a multi-center, prospective EU observational study called STRAIT, to evaluate the Safety and Performance of the BOBBY Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke.
The BOBBY Balloon Guide Catheter is currently approved in Europe and in North America. It has been designed to streamline balloon preparation, while improving navigability and ensuring compatibility with the SOFIA™ Plus 6Fr Aspiration Catheter.
The first patient for the STRAIT study was enrolled at the site of the Principal Investigator PD. Dr. med. Tobias Boeckh-Behrens, Department of Diagnostic and Interventional Neuro Radiology (Klinikum rechts der Isar der Technischen Universität München). Dr. med. Christian Maegerlein who treated the patient with the BOBBY device commented, “A severe stroke case with a left carotid occlusion was successfully treated with the use of the BOBBY, resulting in a first pass TICI 3, 20 minutes after groin puncture. We were pleased with the excellent performance of the BOBBY BGC with the SOFIA Plus 6Fr Aspiration Catheter, Headway™ Microcatheter, Traxcess™ EX Guidewire and the 6x40 stent retriever revascularization device.”
Carsten Schroeder, President and CEO of MicroVention, Inc. noted that, “The STRAIT trial is intended to provide clinical evidence that MicroVention’s new balloon guide catheter can effectively contribute to improved clinical outcomes.”
About the BOBBY™ Balloon Guide Catheter
About the Headway™ Microcatheter
About Traxcess™ EX Guidewire
About the SOFIA™ Aspiration Catheter
Indications may vary by region. Please consult the device Instruction For Use for more information.
About MicroVention, Inc.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.